Loading...
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin
Caracciolo, Daniele Juli, Giada Riillo, Caterina Coricello, Adriana Vasile, Francesca Pollastri, Sara Rocca, Roberta Scionti, Francesca Polerà , Nicoletta Grillone, Katia
Caracciolo, Daniele
Juli, Giada
Riillo, Caterina
Coricello, Adriana
Vasile, Francesca
Pollastri, Sara
Rocca, Roberta
Scionti, Francesca
Polerà , Nicoletta
Grillone, Katia
Citations
Altmetric:
Genre
Journal article
Date
2022-10-22
Advisor
Committee member
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.1186/s12967-022-03705-z
Abstract
Background: DNA ligases are crucial for DNA repair and cell replication since they catalyze the final steps in which DNA breaks are joined. DNA Ligase III (LIG3) exerts a pivotal role in Alternative-Non-Homologous End Joining Repair (Alt-NHEJ), an error-prone DNA repair pathway often up-regulated in genomically unstable cancer, such as Multiple Myeloma (MM). Based on the three-dimensional (3D) LIG3 structure, we performed a computational screening to identify LIG3-targeting natural compounds as potential candidates to counteract Alt-NHEJ activity in MM. Methods: Virtual screening was conducted by interrogating the Phenol Explorer database. Validation of binding to LIG3 recombinant protein was performed by Saturation Transfer Difference (STD)—nuclear magnetic resonance (NMR) experiments. Cell viability was analyzed by Cell Titer-Glo assay; apoptosis was evaluated by flow cytometric analysis following Annexin V-7AAD staining. Alt-NHEJ repair modulation was evaluated using plasmid re-joining assay and Cytoscan HD. DNA Damage Response protein levels were analyzed by Western blot of whole and fractionated protein extracts and immunofluorescence analysis. The mitochondrial DNA (mtDNA) copy number was determined by qPCR. In vivo activity was evaluated in NOD-SCID mice subcutaneously engrafted with MM cells. Results: Here, we provide evidence that a natural flavonoid Rhamnetin (RHM), selected by a computational approach, counteracts LIG3 activity and killed Alt-NHEJ-dependent MM cells. Indeed, Nuclear Magnetic Resonance (NMR) showed binding of RHM to LIG3 protein and functional experiments revealed that RHM interferes with LIG3-driven nuclear and mitochondrial DNA repair, leading to significant anti-MM activity in vitro and in vivo. Conclusion: Taken together, our findings provide proof of concept that RHM targets LIG3 addiction in MM and may represent therefore a novel promising anti-tumor natural agent to be investigated in an early clinical setting.
Description
Citation
Caracciolo, D., Juli, G., Riillo, C. et al. Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin. J Transl Med 20, 482 (2022). https://doi.org/10.1186/s12967-022-03705-z
Citation to related work
BMC
Has part
Journal of Translational Medicine, Vol. 20
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu